Keymed Biosciences Inc. (HKG:2162)
74.30
-2.10 (-2.75%)
Sep 10, 2026, 11:59 AM HKT
Keymed Biosciences Revenue
Keymed Biosciences had revenue of 617.07M CNY in the half year ending June 30, 2026, with 1,028.47% growth. This brings the company's revenue in the last twelve months to 834.63M, down -4.31% year-over-year. In the year 2025, Keymed Biosciences had annual revenue of 716.31M with 67.31% growth.
Revenue (ttm)
834.63M CNY
Revenue Growth
-4.31%
P/S Ratio
23.36
Revenue / Employee
472.08K CNY
Employees
1,768
Market Cap
22.51B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 716.31M | 288.19M | 67.31% |
| Dec 31, 2024 | 428.12M | 74.03M | 20.91% |
| Dec 31, 2023 | 354.10M | 254.03M | 253.87% |
| Dec 31, 2022 | 100.06M | -10.21M | -9.26% |
| Dec 31, 2021 | 110.27M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 20.63B |
| Shanghai Henlius Biotech | 8.58B |
| Zai Lab | 3.53B |
| Shanghai Junshi Biosciences | 3.49B |
| InnoCare Pharma | 3.21B |
| HBM Holdings | 1.40B |
| InSilico Medicine Cayman TopCo | 1.06B |
| Duality Biotherapeutics | 972.22M |